Consensus lacking on ‘value’ for new anti-cancer drugs

8 December 2021 - The high price tag of new anticancer drugs has fuelled debate about the value of these treatments, ...

Read more →

Drug pricing debate redux — should cost effectiveness analysis be used now to price pharmaceuticals?

13 November 2021 - The idea of permitting the government to negotiate pharmaceutical prices raises a question about the basis for ...

Read more →

Paying for cancer drugs that prove their benefit

11 October 2021 - The United States pays prices for brand name drugs that are estimated to be 256% higher than ...

Read more →

Controversy over using quality adjusted life years in cost effectiveness analyses: a systematic literature review

8 September 2021 - Researchers and policy makers in the US are exploring the implementation of health technology assessment and value ...

Read more →

Accelerated approval - an unexpected pathway to value-based pricing?

18 August 2021 - Accelerated approval is an important regulatory pathway that provides early access to treatments for patients with serious ...

Read more →

Aduhelm pros and cons debated at ICER meeting

16 July 2021 - Biogen officials defended the company's Alzheimer's drug and criticised ICER's cost effectiveness report today at a meeting ...

Read more →

Are drugs priced in accordance with value? A comparison of value based and net prices using Institute for Clinical and Economic Review reports

19 June 2021 - The Institute for Clinical and Economic Review is an independent organisation that reviews drugs and devices with ...

Read more →

Rather than turning its back on the QALY, pharma should collaborate on efforts to improve it

7 May 2021 - A key element in the long-simmering debate on reining in drug prices in the United States ...

Read more →

The thorny issue of value alignment: how development-focused health technology assessment can help find win–win situations for patients and health care systems and commercial investors

20 April 2021 - We agree that there is always likely to be some tension between commercial interests and maximising societal ...

Read more →

On the role of cost effectiveness thresholds in health care priority setting

25 January 2021 - In the past few years, empirical estimates of the marginal cost at which health care produces a ...

Read more →

ICER opens nominations for new members of its voting panels

2 December 2020 - Independent panel members debate the evidence on the effectiveness and value of new drugs and other ...

Read more →

The real worth of cancer drugs

1 December 2020 - In November, 2020, we witnessed one of the most awaited elections in recent times—the USA elected Joe ...

Read more →

Will COVID-19 vaccines be cost effective—and does it matter?

26 November 2020 - The costs of other pandemic measures mean that covid-19 vaccines will probably turn out to be ...

Read more →

Consideration of value-based pricing for treatments and vaccines is important, even in the COVID-19 pandemic

19 November 2020 - Prices send signals about consumer preferences and thus stimulate producers to make more of what people want. ...

Read more →

A health opportunity cost threshold for cost effectiveness analysis in the United State

3 November 2020 - Cost effectiveness analysis is an important tool for informing treatment coverage and pricing decisions, yet no consensus ...

Read more →